Gene Therapy: Rewriting the Code of Life | Drip Bears

Gene therapy, pioneered by scientists like William French Anderson and Martin Cline in the 1980s, has evolved into a promising treatment for genetic disorders. By leveraging viral vectors, such as adeno-associated virus (AAV), to deliver healthy copies of a defective gene to cells, gene therapy aims to restore normal gene function. With a Vibe score of 8, indicating significant cultural energy, gene therapy has sparked intense debate, particularly regarding its potential to treat complex conditions like sickle cell anemia and muscular dystrophy. However, concerns about safety, efficacy, and accessibility have led to a Controversy spectrum rating of 6, reflecting the ongoing discussions among experts. As of 2022, companies like Biogen and Novartis are at the forefront of gene therapy development, with the global market projected to reach $13.4 billion by 2025. The influence of gene therapy can be seen in the work of researchers like Jennifer Doudna, who has made significant contributions to the field of CRISPR gene editing, with an Entity relationship to the broader topic of genetic engineering.